Global Parkinson's Disease (PD) Drugs Market 2017-2021: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis & Teva Pharmaceutical Industries

DUBLIN, September 6, 2017 /PRNewswire/ --

The "Global Parkinson's Disease (PD) Drugs Market 2017-2021" report has been added to Research and Markets' offering.

The global parkinson's disease (PD) drugs market is forecast to grow at a CAGR of 3.81% during the period 2017-2021.

The report, Global Parkinson's Disease (PD) Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is emergence of biomarkers. The global PD drugs market is primarily dominated by dopamine agonist, MAO inhibitors, AChE inhibitors, glutamate inhibitors, and others. Use of these drugs for the treatment of different types of neurodegenerative disorders such as Lewy bodies dementia, movement disorder, and PD indicates that these disorders have common pathological conditions.

According to the report, one driver in the market is rise in geriatric population. PD is a neurological disorder, often characterized by a decline in motor functions, cognitive, and memory impairments. The cognitive impairment associated with PD may include symptoms such as memory loss, difficulty in understanding words, inability to carry out voluntary activities, failure to identify objects, and others. The risk of developing PD increases with age and is more common among older people. As per the CDC, the projected demographic changes in the US and increasing geriatric population demand better understanding of the pathogenesis of various neurological diseases, including dementia, among older population and is a growing public health concern.

Key vendors

• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical Industries

Other prominent vendors

• AbbVie
• Abital Pharma
• Addex Therapeutics
• Biogen
• Eisai
• Others
  

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Pipeline Landscape

Part 07: Market Segmentation By Drug Class

Part 08: Market Segmentation Based On Geography

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Key Vendor Analysis

Part 14: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/94qrsg/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-parkinsons-disease-pd-drugs-market-2017-2021-key-vendors-are--boehringer-ingelheim-glaxosmithkline-novartis--teva-pharmaceutical-industries-300514964.html

SOURCE Research and Markets